Rolls-Royce Nears Deal to Offload Its £4 Billion UK Pension Pot
Save
Rolls-Royce Holdings Plc is nearing a deal to offload its UK pension pot to an insurer, a move that would take almost £4 billion ($5.4 billion) in liabilities off the aircraft engine maker's balance sheet.
The biggest UK manufacturer may announce a deal with pension buyout firm Pension Insurance Corp. as soon as this month, according to people familiar with the negotiations. Talks could still be delayed or fall apart, said the people, asking not be identified discussing private information.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
4 hours ago
- Business Upturn
Goldman Sachs keeps buy on USL with Rs 1,575 target, says long-term tailwinds intact
By Markets Desk Published on August 18, 2025, 08:22 IST Goldman Sachs has maintained its buy call on United Spirits Limited (USL) with a target price of ₹1,575 after the company delivered a first-quarter performance ahead of topline estimates. The brokerage noted that volume growth was muted when adjusted for the impact of Andhra Pradesh, but said the overall showing was encouraging given the operating environment. Goldman Sachs expects structural benefits from the UK-India free trade agreement to begin accruing from the first quarter of FY27, potentially providing tailwinds for both growth and margins. It has, however, trimmed FY26–28 earnings per share estimates by 2–4% to reflect near-term pressures. Despite the cut, the brokerage remains constructive on USL's medium-term outlook, citing strong premiumisation trends and the company's ability to expand margins through disciplined cost control. Disclaimer: The views and recommendations made in this article are those of Goldman Sachs. This article does not constitute investment advice. Investors should consult their financial advisors before making any investment decisions. Ahmedabad Plane Crash Markets Desk at
Yahoo
8 hours ago
- Yahoo
Clover Health (CLOV) Achieves Profitability as Medicare Advantage Membership Surges
We recently published . ABC is one of the best healthcare stocks. Clover Health Investments, Corp. (NASDAQ:CLOV) is one of the best healthcare stocks. It is a Medicare Advantage insurer that leverages its AI-powered Clover Assistant platform to improve health outcomes, particularly for chronic conditions such as congestive heart failure. Its PPO-focused model offers broader network access compared to typical HMO plans, aiming to reduce hospitalizations and readmissions through advanced analytics and clinical decision support. In Q2 2025, Clover Health Investments, Corp. (NASDAQ:CLOV) reported a 32% year-over-year increase in Medicare Advantage membership, reaching over 106,000 members. Insurance revenue grew 34% to about $470 million, with adjusted EBITDA and net income both at roughly $17 million, maintaining profitability despite elevated sector-wide medical costs. Clover Assistant has demonstrated measurable impact, including an 18% reduction in hospitalizations and 25% fewer 30-day readmissions for heart failure patients under its care model. The business plans to use these results as a competitive differentiator and is expanding the platform to other risk-bearing organizations. Photo by National Cancer Institute on Unsplash The corporation also improved its Medicare star ratings, with PPO plans projected to rise from 3.5 stars in 2025 to 4.0 stars in 2026, boosting reimbursement potential and market competitiveness. While facing rising costs from supplemental benefits and regulatory changes, Clover Health Investments, Corp. (NASDAQ:CLOV) is pursuing cost-efficiency measures such as renegotiating partnerships and expects these efforts, along with regulatory adjustments, to help ease pressures by 2026. While we acknowledge the potential of CLOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Business Insider
9 hours ago
- Business Insider
British Bank Standard Chartered's (STAN) Stock Falls 9% on Reports of U.S. Probe
Shares of British bank Standard Chartered (STAN) are down 9% after a U.S. Republican lawmaker wrote to Attorney General Pam Bondi asking for action to be taken against the bank for alleged 'sanctions evasion.' Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Elise Stefanik, a New York Republican, wrote in a letter posted to social media that a special attorney should be appointed to look into Standard Chartered's alleged failings. The London-based bank has been investigated over sanctions in the past. Standard Chartered was fined $1.1 billion in 2019 by U.S. and U.K. authorities for evading sanctions and lacking proper money-laundering controls. The lender is currently facing a $1.9 billion lawsuit in the United Kingdom by investors over Iran sanctions violations. Bank's Response Standard Chartered was quick to respond to the allegations made by Representative Stefanik. In a statement, the bank said that 'the underlying allegations — including the claim that there are $9.6 billion in unlawful transactions — are entirely false and have been rejected by the U.S. courts multiple times.' Standard Chartered added that it will 'fully cooperate' with any relevant authority. Stefanik also alleged that the New York Attorney General's Office, which helps oversee most foreign banks operating in the U.S., did not take action on allegations against Standard Chartered in the past. Stefanik is requesting that the acting U.S. Attorney for New Jersey be in charge of a new probe into the British bank. Is STAN Stock a Buy? The stock of Standard Chartered has a consensus Moderate Buy rating among nine Wall Street analysts. That rating is based on three Buy and six Hold recommendations issued in the last three months. The average STAN price target of 1,356.22p implies 3.89% upside from current levels.
